علاج داء كرون المتوسط إلى الشديد في حالة مغفرة خالية من الكورتيكوستيرويدات أثناء العلاج المركب

References

• In adult outpatients with moderate-to-severely active CD who are in corticosteroid-free clinical remission for at least 6 months on combination therapy with TNF antagonists and an immunomodulator, the AGA SUGGESTS withdrawing the IMMUNOMODULATOR.
• In adult outpatients with moderate-to-severely active Crohn's disease who are in corticosteroid-free clinical remission for at least 6 months on combination therapy of TNF antagonists and an immunomodulator, the AGA suggests AGAINST withdrawal of the TNF ANTAGONIST.
• There was no significant difference in the overall risk of relapse with immunomodulator withdrawal compared with continued combination therapy (16.8% vs 14.9%; RR, 1.15; 95% CI, 0.75–1.76) (Supplementary Figure 12).